RhoGAM Administration After Delivery
Administer RhoGAM 300 µg intramuscularly within 72 hours of delivery to all Rh-negative mothers who deliver an Rh-positive infant and have no pre-existing anti-D antibodies.
Timing and Dosing
The standard postpartum dose is 300 µg (1500 IU) administered within 72 hours of delivery 1. This timing is critical—the evidence demonstrates that postpartum anti-D prophylaxis reduces alloimmunization rates from 13-17% down to 1-2% when given appropriately 2, 3. Historical data from the Liverpool-Baltimore trial showed a 90% reduction in alloimmunization at 6 months postpartum when anti-D was given immediately after delivery compared to untreated patients 3.
Extended Window for Administration
If the 72-hour window is missed, still administer RhoGAM up to 28 days postpartum 4. While optimal efficacy occurs within 72 hours, late administration provides some protection and is preferable to no prophylaxis at all 4.
Assessment for Additional Dosing
Assess for fetomaternal hemorrhage (FMH) exceeding 15 mL of fetal red blood cells (approximately 30 mL of whole fetal blood) 1, 4. The standard 300 µg dose covers up to 15 mL of fetal RBCs. If FMH exceeds this volume:
- Administer an additional 10 µg (or 20 µg per mL of RBCs per the FDA label) for every 0.5 mL of fetal red blood cells above 15 mL 1, 4
- Round up to the next whole syringe 1
Testing for FMH volume is particularly important after events associated with placental trauma: placental abruption, blunt abdominal trauma, or significant antepartum bleeding 4.
Critical Verification Steps
Before administration, confirm:
- Mother is Rh-negative (D-negative)
- Infant is Rh-positive (D-positive) or blood type unknown 1
- Mother has no pre-existing anti-D antibodies (unsensitized)
- Do NOT administer to women with "weak D" (Du-positive) 4
Integration with Antepartum Prophylaxis
If the mother received routine antepartum prophylaxis at 28 weeks, she still requires the full postpartum dose if the infant is Rh-positive 3, 1. The antepartum dose does not eliminate the need for postpartum prophylaxis, as nearly 90% of fetomaternal hemorrhage and alloimmunization risk occurs at delivery 3.
Route of Administration
Intramuscular injection only—do not inject intravenously with standard RhoGAM 1. The FDA label explicitly states this is for IM use only. Note that some formulations (like Rhophylac) can be given IV, but standard RhoGAM cannot 1.
Common Pitfalls to Avoid
- Missing the 72-hour window: Have systems in place for immediate postpartum blood typing of infants born to Rh-negative mothers
- Assuming antepartum dose is sufficient: Always give postpartum dose if infant is Rh-positive
- Failing to assess for large FMH: After traumatic deliveries, placental abruption, or manual placental removal, quantify FMH to determine if additional doses are needed
- Administering to sensitized patients: RhoGAM is ineffective once alloimmunization has occurred; check antibody screen
- Giving to obese patients without consideration: Recent case reports suggest obesity (BMI >35) may be a risk factor for prophylaxis failure, though optimal dosing in this population remains unclear 5
Documentation Requirements
Obtain verbal or written informed consent prior to administration, as RhoGAM is a blood product 4. Document the timing of administration, dose given, and any FMH testing results.
Impact on Future Pregnancies
Without postpartum prophylaxis, approximately 17% of Rh-negative women become immunized after delivering an ABO-compatible, Rh-positive infant 3. With appropriate prophylaxis, this drops to 1-2% 2. The introduction of postpartum rhesus prevention programs reduced fetal mortality from Rh hemolytic disease from 120 per 100,000 live births to 1.5 per 100,000 3.